CliniSys software to play major role in supporting cervical screening service

Lab tech provider’s software will support all eight hubs chosen to deliver primary HPV programme

Clinisys ICE will support the HPV screening initiative

CliniSys is set to play a major role in supporting England’s primary HPV screening service after securing contracts to provide its requesting and reporting software to seven out of eight new laboratory hubs.

The company is getting ready to deploy CliniSys ICE to support GP practices and laboratory services across the seven areas of the country, so that family doctors and nurses can order tests and receive the results.

Four out of the eight successful NHS trusts or pathology networks that will be delivering the new service are also CliniSys WinPath laboratory information management system customers.

Matthew Fouracre, marketing manager of CliniSys, said: “England’s cervical screening programme is an important public health intervention that saves thousands of lives every year.

CliniSys ICE is used by practices across the country to order a wide range of tests for patients, and it will be our job to make sure they can be connected into this new service so they can support the women who come forward for cervical screening

“The new primary HPV screening service should make it even more effective, and CliniSys is proud to have been given such a significant role in its rollout.

“CliniSys ICE is used by practices across the country to order a wide range of tests for patients, and it will be our job to make sure they can be connected into this new service so they can support the women who come forward for cervical screening.”

Primary human Papillomavirus, or HPV, screening is a relatively-new way of examining cervical screening samples.

Traditionally, cells from the smear test were the first thing to be examined in a laboratory. But, with the new method, a check for HPV, a common virus transmitted through sexual contact, is the first test carried out.

In 2013, a trial at six laboratories in England indicated that primary HPV screening could reduce the incidence of cervical cancer and the Government committed to rolling out primary HPV screening across the NHS Cervical Screening Programme by the end of this year.

NHS England subsequently invited NHS trusts and pathology networks to become hubs for the new service, covering London, the North East and North West, East and West Midlands, and South Central, South East and South West.

England’s cervical screening programme is an important public health intervention that saves thousands of lives every year

The commissioning board announced the winning bidders in June.

Seven of the eight laboratory services chosen had selected CliniSys to provide ICE as the requesting and results software that would connect them to GPs.

Fouracre said: “We are now looking forward to engaging with NHS England’s regional public health commissioning teams, regional commissioners, and the laboratories themselves on their mobilisation plans for this important new service.”

Companies